Bispecific T cell activating antigen binding molecules

US9914776B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Oliver Ast · Bassersdorf, CH
• Marina BACAC · Schlieren, CH
• Sabine Imhof-Jung · Planegg, DE
• Christiane Jaeger · Wallisellen, CH
• Christian Klein · Iffeldorf, DE
• Stefan Klostermann · Schwanau, DE
• Michael Molhoj · Munich, DE
• Joerg Thomas Regula · Munich, DE
• Wolfgang Schaefer · Sankt Augustin, DE
• Pablo Umana · Wollerau, CH

Key dates

• Filing date: Aug 3, 2015
• Grant date: Mar 13, 2018
• Expiry date: Sep 1, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.